Hormonal
Preoperative use of GLP-1 and GLP-1/GIP receptor agonists significantly reduces surgical site infections, wound dehiscence, and thromboembolic events in patients undergoing elective hernia repair.
If you are scheduled for hernia surgery and take GLP-1 drugs like Ozempic or Mounjaro, do not stop them abruptly without talking to your surgical team. Recent data shows they actually lower your risk of infection and blood clots. Your doctors can use a simple ultrasound on your stomach before anesthesia to check if it's safe to proceed, potentially saving you from stopping a medication that is helping your overall health.
GLP-1 and GLP-1/GIP agonists demonstrate substantial metabolic benefits including weight reduction (10–20%), improved glycemic control, reduced systemic inflammation, and decreased postoperative complications in surgical populations. Recent evidence suggests reduced surgical site infection, thromboembolic events, and wound dehiscence in GLP-1 receptor agonists users.
Why this rating
The paper is a narrative review citing retrospective cohort studies and observational data rather than large-scale RCTs specifically for hernia repair.
Source
Multimodal Prehabilitation for Hernia Repair: Linking Metabolic Modulation and Mechanical Methods
Dan Nicolae Paduraru et al. · Biomedicines · 2025
DOI 10.3390/biomedicines13123117
More from this paper
- Biomechanically calculated repair (BCR) using GRIP/CRIP concepts significantly reduces hernia recurrence rates compared to conventional repair techniques.Moderate
- Botulinum toxin A (BTA) injections and Progressive Preoperative Pneumoperitoneum (PPP) are effective mechanical optimization strategies for loss-of-domain hernias, reducing fascial tension and enabling primary closure.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →